We report a patient who developed Epstein-Barr virus (EBV)-induced transverse myelitis 19 months after unrelated bone marrow transplantation (BMT). The disease was diagnosed by physical examination, serologic determinations, EBV-specific polymerase chain reaction in peripheral blood lymphocytes and cerebrospinal fluid, and characteristic magnetic resonance imaging scan of the spine. The patient was treated with ganciclovir and cytomegalovirus (CMV) hyperimmune globulin. He gradually improved and recovered completely within 4 weeks. This case suggests that ganciclovir and CMV hyperimmune globulin appear to be effective for the treatment of EBV-induced transverse myelitis in immunocompromised patients following BMT. Keywords: Epstein-Barr virus; transverse myelitis; bone marrow transplantation Epstein-Barr virus (EBV)-associated lymphoproliferative disorder is a well-recognized infectious complication in patients receiving bone marrow transplantation (BMT), particularly from unrelated donors.
remission after conditioning with busulphan (4 mg/kg/day ϫ 4 days) and cyclophosphamide (50 mg/kg/day ϫ 4 days). The HLA-matched unrelated donor was seronegative for CMV but had reactivation of EBV at the time of transplantation. Before harvest, the donor's EBV serostatus was positive for viral capsid antigen (VCA) immunoglobulin G (IgG), VCA IgM, early antigen (EA) IgG, and EpsteinBarr nuclear antigen (EBNA) antibodies. The recipient was VCA-IgG positive, VCA-IgM negative and EBNA-antibodies positive. Polymerase chain reaction (PCR) for EBV DNA from buffy coat leukocytes was positive in the donor and negative in the recipient. Acyclovir and CMV hyperimmune globulin (Cytotect; Biotest, Dreieich, Germany) with high titers of EBV antibodies were given as prophylaxis for EBV disease in the early post-transplantation period. Graft-versus-host disease (GVHD) prophylaxis consisted of antithymocyte globulin, cyclosporin A, methotrexate, and prednisolone. The patient developed moderate acute GVHD of the skin and the gastrointestinal tract and received methylprednisolone and FK506 (tacrolimus) instead of cyclosporin A. Because of extensive chronic GVHD with generalized skin and eye involvement he was treated with prednisolone and azathioprine.
Nineteen months after BMT, the patient presented with local back pain and bilateral lower extremity sensory loss. There was a clear sensory level at the 10th thoracic dermatome, below which pain, temperature, light touch, position, and vibratory sensation were absent. Segmental paresthesias and dysesthesias in both feet also occurred. Stretch reflexes and the abdominal and cremasteric reflexes were lost. His gait was markedly ataxic. In addition, sphincter disturbance of the bowel and bladder was present. The white blood cell count was 5.9 ϫ 10 9 /l with granulocytosis. EBV serostatus with increased VCA-IgG antibodies, EAIgG antibodies, EBNA antibodies, positivity for VCA-IgM antibodies and the increased number of EBV-genome copies in peripheral blood lymphocytes (PBL) indicated reactivation of EBV (Table 1) . Extensive serologic testing for CMV, herpes simplex virus (HSV), enterovirus, influenza A and B viruses, rubella, mumps and varizella zoster virus, toxoplasma, mycoplasma, and fungi were either negative or positive at a low titer and did not change in follow-up serum samples. Cerebrospinal fluid (CSF) revealed a mono- EBV = Epstein-Barr virus; PBL = peripheral blood lymphocytes; PCR = polymerase chain reaction; CSF = cerebrospinal fluid; VCA = viral capsid antigen; EA = early antigen; EBNA = Epstein-Barr nuclear antigen; ϩϩϩ = 10 5 EBV-genome copies/ml; ϩ = PCR positivity only in the CSF cell pellet; − = negative; ND = not done.
nuclear pleocytosis and an increase in protein level (Table  1) . PCR for EBV in CSF demonstrated 10 5 EBV-genome copies/ml and was positive in two separate samples, whereas PCR for CMV, HSV, JC virus and enterovirus was negative. Blood and CSF cultures were negative for bacteria and fungi. Immunophenotypic analysis of PBL revealed a very low number of B lymphocytes and naive CD4 ϩ T lymphocytes. An MRI scan of the entire spine was obtained on a 1.5 T MR scanner (Gyroscan ACS II; Philips, Eindhoven, The Netherlands) using different spine coils. The spinal cord appeared widened. The signal was of increased intensity on T2-weighted sequences throughout the cervical and thoracic spinal cord showing intramedullary edema (Figure 1 ). There was enhancement after administration of gadolinium (Magnevist; Schering, Berlin, Germany) on T1-weighted images corresponding to the inflammation (Figure 2 ). The axial and sagittal MRI scans of the spine established the diagnosis of transverse myelitis. A MRI scan of the brain was normal. The patient was treated with ganciclovir at a total dose of 10 mg/kg/day, given intravenously for 4 weeks followed by ganciclovir at a total dose of 60 mg/kg/day, given orally for an additional 4 weeks. CMV hyperimmune globulin (Cytotect; Biotest) with high titers of EBV antibodies (33 U/ml) was administered at a dose of 400 mg/kg three times a week for the first month and twice weekly for the second month after the onset of EBV-induced transverse myelitis. Immunosuppressive treatment with azathioprine for chronic GVHD was discontinued. In addition, the patient received dexamethasone instead of prednisolone for treatment of chronic GVHD. He gradually improved and recovered completely within 4 weeks. Two months after the onset of transverse myelitis EBV-VCA IgM became negative. Several follow-up samples showed a decrease in EBNA antibodies and a decrease in the number of EBVgenome copies in PBL. In the CSF, the pleocytosis and protein elevation resolved and the EBV-specific PCR became negative on two separate samples (Table 1) . Serial MRI scans showed improvements in the lesions in the spinal cord corresponding to the clinical course. An MRI scan 2 months after the onset of the transverse myelitis was normal (Figures 3 and 4) .
Discussion
In patients receiving unrelated BMT, EBV-associated lymphoproliferative disorders have been observed with increasing frequency due to T cell depletion and more effective immunosuppression. 1 Other EBV-induced clinical manifestations are relatively rare. To our knowledge, the present case is the first report of EBV-induced transverse myelitis after BMT. The diagnosis was made by physical examination, serologic determinations, EBV-specific PCR in PBL and CSF and a characteristic MRI scan. The patient had several risk factors for developing EBV disease. The unrelated donor had a reactivation of EBV at the time of transplantation. The prophylactic use of acyclovir prevented EBV disease in the early post-transplantation period. The patient was still immunocompromised more than 1 year after transplantation. He had a very low B lymphocyte number (B lymphocytes 2.5% of all PBL), and needed intravenous Ig supplements regularly because of very low IgG levels (IgG 2.28 g/l). In addition, he was receiving permanently immunosuppressive treatment because of acute and chronic GVHD. All these risk factors may have been contributed to the EBV disease.
The patient had an early sphincter involvement and a clear sensory level characteristic of transverse myelitis. 3 The serum panel of EBV antibodies (VCA IgG, VCA IgM, EA IgG associated with EBNA antibodies) and the increased number of EBV-genome copies in the PBL indicated EBV reactivation. At the onset of transverse myelitis, 10 5 EBV-genome copies/ml were detected in the CSF. All serum samples investigated during the course of the myelitis were EBV-PCR negative. This finding suggests that the presence of EBV in the CSF is due to an active EBV infection within the central nervous system (CNS). An MRI scan demonstrating increased signal intensity of the spinal cord on T2-weighted sequences and gadolinium enhancement were characteristic of transverse myelitis. 4 For ethical reasons we did not perform a biopsy of the spinal cord. The late onset of the acute EBV-induced disease 19 months after BMT, the absence of fever and lymphadenopathy, and the disease course suggested a transverse myelitis rather than a lymphoproliferative disorder. 5 In vitro studies have demonstrated that ganciclovir has more inhibitory effects on EBV replication than do other antiviral drugs. 6 Ishida et al 7 reported a patient with chronic active EBV infection who became resistant to acyclovir but responded to ganciclovir. Successful treatment with ganciclovir has been described in a patient with EBV-induced lymphoproliferative syndrome after solid organ transplantation. 8 Oettle et al 9 reported a patient who developed acute EBV infection during acyclovir prophylaxis after allogeneic BMT. This patient responded to treatment with ganciclovir and intravenous Ig. The potential efficacy of ganciclovir in inhibiting EBV replication in the CNS has been described in a patient with presumed EBV meningo-encephalitis following allogeneic BMT. 10 The present case supports the in vivo efficacy of ganciclovir in combination with intravenous Ig in suppressing EBV replication in the CNS. Similar data were obtained by Delone et al. 11 They reported a patient with EBV infection following kidney transplantation who was successfully treated with ganciclovir and CMV hyperimmune globulin. The authors emphasize the potential benefit of CMV hyperimmune globulin because of high titers of EBV antibodies as we found in our case.
We conclude that ganciclovir and CMV hyperimmune globulin appear to be effective for the treatment of EBVinduced transverse myelitis in immunocompromised patients following BMT.
